Sign Out
Pregnancy: The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Intravenously administered IgG has been shown to cross the placenta, increasingly during the third trimester. Pentaglobin also contains IgM which does not cross the placenta. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.
Breastfeeding: IgG is excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry. IgM is not excreted into the milk.
Fertility: Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.
